 -- Indicated for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to POMC, PCSK1 or LEPR deficiency confirmed by genetic testing -- -- Approval supports companys approach to address rare genetic diseases of obesity associated with an impaired MC4 receptor pathway -- 